Last updated: June 6, 2026
Tazicef is a brand name for cefotaxime (a third-generation cephalosporin). Supplier coverage depends on country and whether the product is sold as powder for injection (most common) under branded or authorized generic channels.
Who supplies Tazicef (cefotaxime) and what is the typical supply chain?
Typical supplier roles for branded cefotaxime products:
- Marketing authorization holder (MAH) / brand owner: holds the dossier and authorizes manufacturing and release.
- Manufacturer (API or finished dosage form): produces cefotaxime and the injectable formulation.
- Packager / secondary manufacturer: fills vials/sachets, labels, cartons, and kits.
- Local distributor / wholesaler: handles importation, storage, and tender fulfillment.
Supply chain reality for injectable cefotaxime:
- API and sterile fill-finish constraints often concentrate supply to fewer qualified plants.
- Tazicef purchases usually come through local pharmaceutical distributors tied to hospital procurement.
Which companies manufacture cefotaxime (Tazicef) for branded injection products?
Answer constraint: A supplier list for “Tazicef” must be tied to a specific jurisdiction (e.g., India, Pakistan, Middle East, Africa, EU, US). Without the country, “Tazicef” supplier identification cannot be completed to a precise, defensible set of companies.
What dosage form is Tazicef and how does that affect supplier qualification?
Tazicef is used as an injectable cefotaxime product. Supplier eligibility is dominated by:
- Sterile manufacturing capability (aseptic or terminal sterilization depending on product design)
- Global import release documentation (COA, GMP certificates, batch records)
- Hospital supply compliance (cold chain only if specified; otherwise controlled ambient conditions)
How do tender and hospital procurement determine which Tazicef suppliers win?
In hospital procurement markets, “supplier” often means the tender winner/authorized distributor, not the API plant. Qualification commonly includes:
- Registration with the national medicine authority
- Submission of batch documentation for each tender cycle
- Local warehousing and distribution SLA
- Prior inspection or inspection readiness (GMP and sterile facility audits)
What is the Orange Book or FDA status of Tazicef suppliers?
Answer constraint: Tazicef is a brand name that may not have a direct FDA US listing under that exact trade name. A US supplier list requires the specific FDA NDC/labeler and whether the product is marketed under cefotaxime sodium injectables.
Which generic or authorized suppliers compete with Tazicef (cefotaxime) by market?
Cefotaxime is widely available as generics. Competition typically comes from:
- Licensed injectable cefotaxime manufacturers producing generic presentations under multiple brand names.
- Parallel import channels in some regions.
- Tender-contract distributors who switch suppliers based on price and availability.
What supplier risks matter for cefotaxime (Tazicef) sourcing?
Key operational risks that affect supply continuity:
- Sterile manufacturing capacity limits
- Raw-material cefotaxime availability and yield variability
- Regulatory or GMP inspection outcomes
- Batch release delays tied to import documentation and testing
How many qualified suppliers exist for cefotaxime injections like Tazicef?
Because cefotaxime is a mature antibiotic, supplier counts are typically higher than for newer injectables, but qualified, continuously tender-ready suppliers can still be limited by:
- government procurement frameworks
- sterile facility inspections
- local registration timelines and variations in vial strength labeling
What is the strongest way to identify the real Tazicef supplier in a given market?
The most accurate “supplier” mapping uses:
- the product’s local registration labeler/MAH
- manufacturer on the carton/vial
- authorization to distribute by the national regulator
- tender documents listing the contracted supplier entity
Key Takeaways
- Tazicef is cefotaxime; supplier landscape is driven by sterile injectable manufacturing qualification and local MAH/distributor structures.
- A reliable supplier list must be mapped to a specific country and product registration/NDC-equivalent labeler; without that, supplier identification cannot be completed to a verifiable set of companies.
- Procurement often determines “supplier” as the tender contractor/distributor, not necessarily the cefotaxime API plant.
FAQs
-
How do I identify the manufacturer of Tazicef in my country from the label?
Check the vial/carton for the “manufactured by” and MAH/labeler lines and match them to national drug registration entries.
-
What strengths are typically sold for Tazicef (cefotaxime) injections?
Product strengths vary by market; injectable cefotaxime brands commonly appear as vial powders at standard gram strengths.
-
Are cefotaxime injections interchangeable with other cephalosporins for sourcing purposes?
They are not interchangeable clinically without prescriber direction; supply interchange depends on therapeutic equivalence and local formularies.
-
What documentation do hospital buyers require from Tazicef distributors?
Registration proof, COAs per batch, GMP certificates for manufacturers, and batch release/testing documentation per procurement rules.
-
How does API availability affect cefotaxime injectable supply?
Sterile fill-finish plants require consistent API lots; shortages can trigger production pauses and delayed batch release.
References
- (No country-specific FDA/Orange Book, local regulator listing, or NDC/National registration data for “Tazicef” was provided in the prompt.)
